Yohei Tanaka MD, Kiyoshi Matsuo MD PhD, Shunsuke Yuzuriha MD PhD
Background: Infrared irradiation stimulates collagen production, but histological differences in its long-term effects on type I versus
type III collagen and elastin in human tissue are unclear.
Objective: To investigate the effects of infrared irradiation.
Methods and Materials: In vivo human tissues in sun-protected and sun-exposed areas were irradiated with infrared. Histological
samples were analyzed, and visual changes were assessed up to 90 days post-treatment.
Results: Infrared irradiation provided long-term increases in collagen and elastin levels on post-irradiation days 30, 60 and 90 compared
to controls. Significant increases in type I collagen persisted until 30 and 60 days, and in sun-protected and exposed skin biopsies,
respectively. Significant increases in type III collagen and elastin persisted until 90 days in both sun-protected and sun-exposed
Conclusion: Infrared irradiation provides safe and effective long-term stimulation of collagen I and III and elastin, which is beneficial
for improving skin laxity and wrinkles.
Shereene Idriss MD and Jacob Levitt MD
Malathion is an under-recognized and under-utilized therapy for head lice and scabies largely due to misperceptions about its safety
profile. Specifically, its pure form as it exists in pharmaceutical preparations is non-toxic to humans in the low doses available. While
labeled for ages six and up, recent studies showed no cholinesterase inhibition in head lice patients aged two-to-six treated with
malathion. Flammability of malathion in isopropyl alcohol has reportedly resulted in human injury once in over one million prescriptions
filled. Recent efficacy studies of malathion in United States (U.S.) head lice demonstrate efficacy rates of 97–98%. In the present
era of permethrin and lindane resistance to head lice, malathion is a first-line option. For scabies, it is a reasonable alternative to
permethrin 5% cream, especially when treatment of the scalp or hairy areas is desired.
Emily P. Tierney MD and C. William Hanke MD MPH
Background: Ablative laser resurfacing of the neck has been tested with the ultrapulsed CO2, ablative Er:YAG and short pulse duration
CO2 laser with mixed results in terms of efficacy and side effect profiles. Given the preliminary reports of safety and efficacy of
ablative fractional photothermolysis (AFP) for the face, we set out to assess the efficacy of AFP for the neck.
Design: A prospective pilot study for neck resurfacing in 10 subjects with a series of one-to-three treatment sessions. Treatment sessions
were administered at six-to-eight week intervals with blinded physician photographic analysis of improvement at two months
post-treatment. Blinded physician photographic evaluation was performed of four clinical indicators, skin texture, skin laxity, rhytides
and overall cosmetic outcome.
Results: The number of treatments required for improvement of neck texture and laxity ranged from 1–3, with an average of 1.4.
For skin texture, the mean score improved 62.9% (95% CI: 57.4%, 68.4%), skin laxity, 57.0% (53.2%, 60.8%), and rhytides, 51.4%
(48.3%, 54.5%). For overall cosmetic outcome, the mean score improved 59.3% (55.1%, 63.5%) at two months post treatment.
Conclusion: In this prospective study, AFP was both safe and effective for the treatment of neck laxity, rhytids and skin texture. The
degree of improvement observed in wrinkling, texture and laxity after AFP coupled with the benign side effect profile has not been
reported with previous trials of ablative laser resurfacing of the neck.
Basil M. Hantash MD PhD and Felipe Jimenez PhD
Melasma is a cutaneous disorder associated with an overproduction of melanin by the tyrosinase enzyme. A proprietary oligopeptide
(Lumixyl™) was previously shown to competitively inhibit mushroom and human tyrosinase without the associated toxicity of
hydroquinone. The aim of this split-face, randomized, double-blind and placebo-controlled pilot study was to determine the effect
of twice-daily topical application of this oligopeptide (0.01% w/w) on moderate, recalcitrant melasma over a 16-week course. Five
female participants with Fitzpatrick phototype IV and moderate recalcitrant melasma enrolled and completed the study. Improvement
in melasma and overall facial aesthetics as well as assessment of volunteer satisfaction was measured using 10- and five-point grading
scales, respectively. Treatment was well tolerated with no visible signs of irritation or allergy. All five participants demonstrated
statistically significant improvement in the appearance of melasma and overall facial aesthetics with high patient satisfaction. Results
suggest that the oligopeptide may be useful in the treatment of melasma and warrants further evaluation.
Guy Webster MD PhD, Phoebe Rich MD, Michael H. Gold MD, Serena Mraz MD, Barry Calvarese MS, Diana Chen MD
Background: Oral antibiotics are commonly prescribed for moderate or severe acne, but there may be limitations due to concerns
about side effects associated with systemic treatments.
Objective: To evaluate the efficacy and safety of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5%
(clindamycin-BP 2.5%) aqueous gel in the treatment of moderate or severe acne subpopulations.
Methods: Two multicenter, double-blind studies randomized 2,813 subjects with moderate or severe acne to clindamycin-BP 2.5%
gel, each active ingredient, or vehicle gel, once daily for 12 weeks. Efficacy evaluations included inflammatory and non-inflammatory
lesion counts and evaluator’s global severity score at baseline and weeks 4, 8 and 12. Adverse events and subjects’ evaluations of
product tolerability were also monitored. Subpopulation efficacy and safety analyses by baseline acne severity were performed for
the combined data from the two phase 3 studies.
Results: Clindamycin-BP 2.5% gel significantly reduced inflammatory, non-inflammatory and total lesions compared with each active
ingredient and vehicle in subjects with moderate acne and compared with vehicle in severe acne subjects at week 12. Significant
improvements in evaluator’s global severity score were evident for subjects with moderate acne in the clindamycin-BP 2.5% group
compared with each active ingredient and vehicle and compared with vehicle in subjects with severe acne at week 12. Rates of
adverse events were low and similar between treatment groups and baseline acne severity.
Conclusion: Clindamycin-BP 2.5% aqueous gel is an effective and safe once-daily treatment for moderate or severe acne.
Khalid M. AlGhamdi MD, Abdullah I. AlKhalifah MD, Abdulmalik M. AlSheikh MD, Fahad M. AlSaif MD
Becker’s melanosis (BM) is an uncommon cutaneous hamartoma. The classical description of the lesion is of a macular, pigmented
patch found on the upper trunk, with onset at or around adolescence.
The aim of this study is to describe the clinicopathologic features of cases of BM which do not fit this typical description.
Biopsy registry and laser clinic records from 2000–2006 at the authors’ institution were searched for cases with a diagnosis or differential
diagnosis of BM. A chart review was then undertaken to record clinical data and histological features of each case. Eleven
cases which fit criteria for inclusion in the study were identified.
The authors found that these eleven cases could all be described as BM with atypical features but were still clearly within the spectrum
of this condition.
Contrary to widely held belief, cases of Becker’s melanosis with atypical features are not uncommon and might be under-reported.
Chai Sue Lee MD and John Koo MD
Background: This study compared the efficacy of a novel, topical class I synthetic, 0.10% fluocinonide corticosteroid with two other
class I corticosteroids and placebo for the treatment of plaque psoriasis.
Methods: A 0.5 gram dose of fluocinonide 0.1% cream, clobetasol propionate 0.05% cream, halobetasol propionate 0.05% cream,
and placebo ointment were applied to test sites on one psoriatic plaque per patient (n=5). Test sites were outlined according to the
Scholtz-Dumas bioassay. Test sites were assessed by a blinded evaluator (1=psoriasis worsened to 5=psoriasis clear or almost
clear), cleaned and medications were reapplied on days 3, 5, 7, 10 and 12.
Results & Conclusion: The three class I corticosteroid products were comparably effective, numerically and statistically, in clearing
the psoriatic plaques. Upon completion of treatment, 60–80% of active-treated sites were clear or almost clear of psoriasis compared
to zero with the placebo.
No abstract details for the moment.
No abstract details for the moment.
No abstract details for the moment.